Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Group 1 - argenex SE (ARGX) is a notable stock in the Medical sector, currently outperforming its peers with a year-to-date return of approximately 54.7% compared to the sector average of 3.1% [4] - The Medical group ranks 4 within the Zacks Sector Rank, which includes 16 different groups [2] - The Zacks Rank system indicates that argenex SE has a Zacks Rank of 2 (Buy), with a significant increase of 478% in the consensus estimate for full-year earnings over the past three months, reflecting improved analyst sentiment [3] Group 2 - argenex SE belongs to the Medical - Biomedical and Genetics industry, which consists of 504 companies and currently ranks 94 in the Zacks Industry Rank, while this industry has seen an average loss of 2.3% this year [5] - Another outperforming stock in the Medical sector is Novartis (NVS), which has a year-to-date return of 9.5% and also holds a Zacks Rank of 2 (Buy) [4][5] - The Large Cap Pharmaceuticals industry, where Novartis is categorized, has 12 stocks and has increased by 12.7% since the beginning of the year, ranking 88 in the Zacks Industry Rank [6]